DR. DAVID ERIC GERBER M.D.
Prescription History 1336295039
Internal Medicine - Medical Oncology in Dallas, TX


Quality Rating: 74.59 out of 100 score

NPI Status: Active since January 26, 2007

Contact Information

2201 INWOOD RD SEAY BIOMEDICAL BUILDING 2ND FLOOR
DALLAS, TX
ZIP 75390
Phone: (214) 645-4673

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. DAVID ERIC GERBER M.D., an active Medical Oncology specialist practicing in Dallas, TX. Our medical registry currently tracks 9 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 177 documented patient claims. Among these therapy options, the most frequently utilized medication is Prochlorperazine Maleate, which accounts for 34 claims alone.


Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 388
TX State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills33.5
Peer Average Days Supply411
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $331.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.42

State Avg Cost Per Claim

$13.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 14.0
Days Supply 420
TX State Average Benchmarks
Peer Average Claims76.0
Peer Average 30-Day Fills120.8
Peer Average Days Supply3,403
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 84.2% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,521.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$460.11

State Avg Cost Per Claim

$810.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Erlotinib Hcl

Generic Formulation: Erlotinib HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
TX State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills14.1
Peer Average Days Supply420
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,566.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$130.55

State Avg Cost Per Claim

$1,777.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.

Therapeutic Applications

Erlotinib is used to treat lung and pancreatic cancer. It works by slowing or stopping the growth of cancer cells.

Hydrocodone-Acetaminophen

Generic Formulation: Hydrocodone/AcetaminophenSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 217
TX State Average Benchmarks
Peer Average Claims121.0
Peer Average 30-Day Fills121.4
Peer Average Days Supply2,775
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 90.9% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $367.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.39

State Avg Cost Per Claim

$24.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to relieve moderate to severe pain. It contains an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen). Hydrocodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Levothyroxine Sodium

Generic Formulation: Levothyroxine SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 25.0
Days Supply 750
TX State Average Benchmarks
Peer Average Claims144.0
Peer Average 30-Day Fills342.9
Peer Average Days Supply10,129
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 89.6% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $134.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.95

State Avg Cost Per Claim

$17.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 212
TX State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.1
Peer Average Days Supply247
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 38.9% more claims than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $188.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.55

State Avg Cost Per Claim

$7.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 311
TX State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply316
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 25.9% more claims than the standard regional baseline profile for TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $513.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.12

State Avg Cost Per Claim

$17.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Tagrisso

Generic Formulation: Osimertinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 600
TX State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.8
Peer Average Days Supply710
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $349,672.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,483.64

State Avg Cost Per Claim

$17,056.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat lung cancer. Osimertinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 21.0
Days Supply 630
TX State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills81.8
Peer Average Days Supply2,343
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.7% less volume than the regional standard for practitioners inside TX. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,005.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$684.50

State Avg Cost Per Claim

$903.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. DAVID ERIC GERBER M.D. provides transparency into local medical care patterns within Dallas, TX.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.